×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

DRUG MAKER AVENTIS OPENS $100 MILLION REVIEW

Global Ad Assignment Is for Diabetes Drug Lantus

Published on .

NEW YORK (AdAge.com) -- Pharmaceutical company Aventis put the estimated $100 million global advertising assignment for its Type 1 and Type 2 diabetes drug Lantus in review, agency executives said.

Aventis declined to comment.

Believed to be pitching for the account are: Omnicom Group's TBWA Worldwide; Interpublic Group of Cos.' McCann-Erickson Worldwide; WPP Group's Y&R Advertising, working with sibling shops Burson-Marsteller and Mediaedge:cia; and Havas' Euro RSCG Worldwide.

Aventis has introduced Lantus in the U.S., England, Germany and, last month, Ireland. It is expected to be launched globally in late 2003.

Most Popular